Survivin the battle against immunosuppression

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 240-241

  Manuel, Edwin R ^a   Blache, Céline A ^a   Ellenhorn, Joshua D I ^b   Diamond, Don J ^a  

^a Division of Translational Vaccine Research   (United States)

^b City of Hope   (United States)

Author keywords

B16F10 melanoma; Salmonella; shRNA; Stat3; Survivin; Synergy

Indexed keywords

BACTERIAL VECTOR; CPG STAT3 SMALL INTERFERING RNA; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 10; INTERLEUKIN 23; IPILIMUMAB; KI 67 ANTIGEN; MELANOMA VACCINE; SALMONELLOSIS VACCINE; SHORT HAIRPIN RNA STAT3 SALMONELLA VACCINE; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; DRUG EFFICACY; GENE SILENCING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MELANOMA; NONHUMAN; NONVIRAL GENE THERAPY; NOTE; PRIORITY JOURNAL; SALMONELLA; TUMOR IMMUNITY; UNSPECIFIED SIDE EFFECT;

EID: 84886944284     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.1.2.18180     Document Type: Note

References (7)

1. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25:267-96; http://dx.doi.org/10.1146/annurev.immunol.25.022106.141609
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; http://dx.doi.org/10.1056/NEJMoa1003466
3. Manuel ER, Blache CA, Paquette R, Kaltcheva TI, Ishizaki H, Ellenhorn JD, et al. Enhancement of cancer vaccine therapy by systemic delivery of a tumortargeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res 2011; 71:4183-91; http://dx.doi.org/10.1158/0008-5472.CAN-10-4676
4. Kortylewski M, Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008; 20:228-33; http://dx.doi.org/10.1016/j.coi.2008.03.010
5. Kortylewski M, Swiderski P, Herrmann A, Wang L, Kowolik C, Kujawski M, et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat Biotechnol 2009; 27:925-32; http://dx.doi.org/10.1038/nbt.1564
6. Schmidt SM, Schag K, Muller MR, Weck MM, Appel S, Kanz L, et al. Survivin is a shared tumorassociated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. Blood 2003; 102:571-6; http://dx.doi.org/10.1182/blood-2002-08-2554
7. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 2003; 3:46-54; http://dx.doi.org/10.1038/nrc968